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ABSTRACT
Several studies have shown that a higher lymphocyte count 3-4 weeks after allogeneic stem cell transplantation
(SCT) is associated with better transplant outcome. However, the factors determining early lymphocyte
recovery are not defined. To further explore the relationship between lymphocyte recovery and outcome we
analyzed lymphocyte counts and other engraftment parameters in 157 patients with leukemia (48 acute
myelogenous leukemia, 80 chronic myelogenous leukemia, and 29 acute lymphoblastic leukemia [ALL])
receiving T cell-depleted myeloablative SCT from an HLA-identical sibling. In multivariate analysis the day 30
absolute lymphocyte count (LC30) above the median of 450/L was associated with improved survival (71% 
5% versus 38%  6%, P < .0001), less relapse (21%  5% versus 44%  7%, P  .009), less nonrelapse
mortality (NRM; 9 3 versus 36% 6%, P< .0001) and less acute graft-versus-host disease (aGVHD) (34%
5% versus 51%  6%, P  .025). The beneficial effect of a higher LC30 influenced outcome in patients with
both standard and high-risk disease but did not affect survival and relapse in ALL.We found that a higher LC30
correlated with higher lymphocyte counts at all time points between 30 and 90 days post-SCT and also with
more rapid neutrophil and platelet engraftment. These results indicate that LC30 is a surrogate for robust
engraftment and identifies an “at-risk” population of patients after T cell-depleted SCT.
© 2007 American Society for Blood and Marrow Transplantation
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LNTRODUCTION
Several studies have shown that early recovery of
he lymphocyte count after allogeneic stem cell trans-
lantation (SCT) is associated with better survival,
educed relapse, and lower transplant-related mortal-
ty (TRM) [1-5]. A recent analysis found that a low
bsolute lymphocyte count (100/L) was also asso-
iated with poor outcome following acute graft-ver-
us-host disease (aGVHD) [6]. We previously reported
mproved transplant outcome for chronic myelogenous
eukemia (CML) in patients with high day 30 lympho-
yte counts (LC30) after T cell-depleted myeloablative r
216tem cell transplantation from an HLA-identical sib-
ing [7]. Natural killer (NK) cells are the ﬁrst lympho-
ytes to recover after peripheral blood stem cell trans-
lantation (PBSCT) and play an important role in the
nnate host defenses. Niederwieser et al. [8] showed in
he early posttransplant period that the majority of
eripheral blood lymphocytes were NK cells, which
an mediate cytotoxicity without prior sensitization
nd may be responsible for early graft-versus-leuke-
ia (GVL) effects [9,10]. We have earlier shown
hat NK cells are the dominant population in the
C30, and that LC30 and NK30 were highly cor-
elated. Furthermore, higher levels of NK30 were
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Transplant Outcome after Allogeneic Stem Cell Transplantation 1217ssociated with improved transplant outcome in
ML after SCT [7].
These ﬁndings suggested that the LC30 may serve
s a surrogate for NK cell recovery. However, the
implicity and reproducibility of LC30 measurement
etween transplant centers encouraged us to investigate
ymphocyte recovery further in a large diverse popula-
ion of transplant recipients to further explore the pre-
ictive value of LC30 and to better elucidate the rela-
ionship of the LC30 with other measurements of
ngraftment at various times posttransplant.
Here we show, in a cohort of 157 patients under-
oing T cell-depleted SCT, that LC30 was correlated
ith standard engraftment parameters and was a pow-
rful predictor of transplant outcome in myeloid ma-
ignancies but not in acute lymphoblastic leukemia.
ATIENTS AND METHODS
tudy Group
One-hundred-sixty consecutive patients with leu-
emias received a T cell-depleted SCT from an HLA-
dentical sibling in NHLBI institutional review board
pproved protocols. The study populations included
0 CML patients previously reported [7]. Written
nformed consent was obtained according to princi-
les outlined in the Declaration of Helsinki. Of these
atients, 157 survived until day 30 and formed the
tudy cohort.
onditioning Regimens and Transplant Approach
Transplant approach, details of cyclosporine
CSA) dosing schedule, posttransplant T cell add-
ack, monitoring of minimal residual disease, chimer-
sm, infection prophylaxis, and CMV monitoring were
escribed previously [7,11]. Three transplant regi-
ens were used: (1) 52 patients received 13.6 Gy
otal-body irradiation (TBI), cyclophosphamide (Cy)
20 mg/kg, standard dose (SD) CSA (target levels
00-400 g/L; (2) 41 received TBI/Cy and low-dose
LD) CSA (target levels 100-200 g/L); (3) 64 re-
eived 12.0 Gy TBI/Cy/ﬂudarabine (Flu) 125 mg/m2
nd LD CSA. All patients received a T cell-depleted
ransplant (dose range 0.2-2.0  105 CD3 cells/kg)
ith delayed donor-lymphocyte infusions 1-3 months
fter transplantation. The stem cell source was gran-
locyte-colony stimulating factor (G-CSF) mobilized
eripheral blood for all patients, except 28 in the ﬁrst
ohort, who received bone marrow (BM) transplants.
ay 30 Lymphocyte Monitoring (LC30)
Of 160 patients transplanted 157 (48 acute my-
logenous leukemia [AML] or myelodysplastic syn-
rome [MDS] that had progressed to AML, 80
hronic myelogenous leukemia [CML], and 29 acute
ymphoblastic leukemia [ALL]) survived to day 30 posttransplant for LC30 evaluation from a routine
lood count (in all cases obtained before any post-
ransplant donor lymphocyte infusion [DLI]). The 3
atients excluded from analysis died from CMV pneu-
onitis day 15, acute respiratory distress syndrome
ay 23, and intracranial hemorrhage day 28 posttrans-
lantation. Their absolute lymphocyte count on day
f death was 140, 289, and 80/L, respectively.
efinitions
Patients with ALL and AML, in ﬁrst complete
emission and patients with CML in the chronic phase
CP) were considered to have standard risk (SR) dis-
ase. All other patients, including those who under-
ent transplantation in CR2 or greater, those with
rimary refractory or relapsed disease, and those with
econdary AML were deﬁned as having high-risk
HR) disease. Overall survival (OS) was calculated
rom the interval between the date of transplantation
nd death, or last follow-up visit. Relapsed disease for
ML and ALL was deﬁned by morphologic or cyto-
enetic evidence, either in peripheral blood or in bone
arrow. Relapsed disease for CML was deﬁned by
ematologic or cytogenetic or molecular evidence of
ecurrence. Nonrelapse mortality (NRM) was deﬁned
s the time from transplantation until death from
nfectious cause, graft failure, GVHD, or any other
ause unrelated to disease. Estimates for relapse,
VHD incidence, and NRM were made using cumu-
ative incidence estimates. Engraftment was deﬁned as
bsolute neutrophil count of 500/L, and unsup-
orted platelet count of 20,000 for 3 consecutive
ays or detection of donor DNA by PCR-short tan-
em repeat (STR).
tatistical Methods
Summary statistics, such as proportions, means,
tandard deviations, 95% conﬁdence intervals (CIs), me-
ians, and ranges, were used to describe the patient
haracteristics, pretransplant variables, and posttrans-
lant outcomes. Standard techniques in survival analysis,
ncluding Kaplan-Meier estimates and the Cox Propor-
ional Hazard Models, were used to estimate the time-
o-event distributions of OS, disease-free survival (DFS)/
urrent leukemia-free survival (LFS), relapse, GVHD,
nd TRM. Statistical associations between pretransplant
ariables were investigated using correlation analysis,
ncluding Pearson’s correlation coefﬁcients and Spear-
an’s rank correlation coefﬁcients, and multiple regres-
ion analysis. Statistical tests based on t-tests, chi-squared
ests, and F-tests were used to evaluate the statistical
igniﬁcance of covariates in multiple regression models
r the Cox proportional hazard models. Variables in-
luded in univariate analysis were: age (continuous, less
han versus greater than or equal median), sex, donor-
atient sex match (female to male versus others), disease
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B. N. Savani et al.1218isk (high risk [HR] versus standard risk [SR]), type of
ransplant (blood and marrow transplantation [BMT]
ersus PBSCT), CD34 dose (continuous, less than ver-
us greater than or equal to median), CD3 dose (0.2
ersus 0.2  105/kg CD3 cells), LC30 (continuous,
ess than versus greater than or equal to median), and
SA dose (SD versus LD). Analysis was performed with
C30 taken as a continuous variable, less than versus
reater than or equal to median for whole cohort and
ach disease category with cohort median and disease
peciﬁc median value of LC30. Multivariate analysis was
erformed using the Cox models. Data analysis was
erformed using SPSS 14 for Windows (SPSS Inc.,
hicago, IL) software.
ESULTS
atients
Cohort distribution and patient characteristics are
hown in Tables 1 and 2, respectively.
Validation of the LC30 as a representative mea-
urement of early lymphocyte recovery
Median LC30 of cohort was 448/L (450 versus
450 taken in a cutoff model for analysis), range:
-3295 (AML 403/L, range: 31-2105; CML 287/
L, range: 0-1498, and ALL 778/L, range: 265-3295)
Figure 1A). Figure 1B shows the absolute lymphocyte
ount on day 30 (LC30), 60 (LC60), and 90 (LC90)
above and below median) posttransplant among pa-
ients who survive at least 90 days after SCT. Patients
ith LC30 above median had higher lymphocyte
ounts on day 14 and retained correspondingly higher
ymphocyte count on day 60 and 90, whereas patients
ith less than or equal to median LC30 had lower
ounts on day 14 and slower recovery on day 60 and
0 than the high LC30 subset. Because day 14 lym-
hocyte counts were very low, we chose the LC30 as
he earliest reliable measurement for subsequent anal-
ses. One hundred three patients received DLI be-
ween day 30 and 45 and day 22 and 60. DLI had no
igniﬁcant impact on LC60 and LC90 recovery com-
ared to LC30 (P .38 for LC60 and 0.24 for LC90).
able 1. Cohort Descriptions
Cohort* n
Stem Cell
Source TBI (Gy)
Flu (125
mg/m2)
Cy
mg/kg
1 28 BM 1360 — 120
2 65 PB 1360 — 120
3 64 PB 1200 125 120
BI indicates total-body irradiation; Flu, Fludarabine; Cy, Cyclo-
phosphamide; BM, bone marrow; PB-G-CSF mobilized periph-
eral blood.
Nonsigniﬁcant difference between cohorts in terms of age (less
than versus greater than or equal to median), sex, disease distri-dbution, disease risk.ransplant Outcome and LC30
Engraftment. Two patients (1.3%, 1 with CML
nd the other ALL) failed to engraft. Both patients
ere rescued successfully after receiving a second
raft. Their transplant outcome in relation to LC30/
K30 was calculated from the second graft.
Median time to neutrophil and platelet engraft-
ent was 16 days (range: 11-39) and 18 (range: 12-
3). Patients with LC30 450/L had faster neutro-
hil engraftment (15.5  0.2 versus 18  0.5 days for
C30 450/L; P  .0001) and faster platelet en-
raftment (18  0.4 versus 22  0.8 days for LC30
450/L; P .0001) (Figure 2). STR chimerism was
vailable in 55 patients. Median time to full donor
ymphoid chimerism was 60 days (range: 14-798).
here was no correlation between LC30 (either as a
ontinuous or a categoric variable) and time to full
onor T cell chimerism (P  .445).
GVHD
Sixty-three patients developed aGVHD grade (II-
V) with a cumulative incidence of 43% 4% (Figure
A). On univariate analysis, risk of aGVHD was asso-
iated with HR disease (57% versus 26% for SR dis-
ase; P  .001), and LC30 450/L (P  .025)
Figure 3A). There was no effect of stem cell source
BMT versus PBSCT), disease type, age, sex, CSA
ose, CD34 and CD3 cell dose on incidence of
GVHD. Multivariate analysis showed that indepen-
able 2. Patient Characteristics
Variables (n  157) Details
ge Median 34 years (range: 10-56)
ex Male 89 (57%); female 68 (43%)
isease distribution AML 48 (31%); ALL 29 (19%);
CML 80 (50%)
isease risk HR 80 (51%); SR 77 (49%)
AML—HR 27, SR 21; ALL—
HR 26, SR 3; CML— HR 27,
SR 53
D34 cell dose (106/kg)† Median 5 (range: 0.78-15.9)
SA dose* LD 105 (67%); SD 52 (33%)
D3 cell dose/kg with graft 0.2  105 64 (41%); >0.2  105
93 (59%)
ollow-up surviving patients Median 52 (range: 12-146)
00 day TRM N  14 (9%)
C30** Median 448/L (range: 0-3295)
ML indicates acute myelogenous leukemia; ALL, acute lympho-
blastic leukemia; CML, chronic myelogenous leukemia; HR,
high risk; SR, standard risk for relapse after SCT; TRM, trans-
plant-related mortality.
SD, standard dose (200-400 g/L), LD, low dose (100-200 g/L).
*HR and SR groups were equally balanced between LC30 greater
than versus less than 450/L (40 versus 37 for SR and 38 versus
42 for HR disease, P  .346).
CD34 cell dose and LC30 were signiﬁcantly correlated (correla-
tion coefﬁcient 0.578, P  .0001).ent factors associated with more aGVHD were HR
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Transplant Outcome after Allogeneic Stem Cell Transplantation 1219isease (relative risk [RR] 3.0, 95% CI 1.7-5.0; P 
0001) and LC30 450/L (RR 1.8, 95% CI 1.1-2.9;
 .027).
hronic GVHD (cGVHD)
Eighty-one of 129 evaluable patients surviving
100 days developed cGVHD (limited 58 [45%];
xtensive 23 [18%]) with a cumulative incidence of
1%  5% (Figure 3B). On univariate analysis, SR
isease (71% versus 53% for HR disease; P  .021),
nd LC30 450/L (P  .01) were associated with
ncreased risk of cGVHD (Figure 3B). There was no
ffect of type of SCT (BMT versus PBSCT), disease
ype, age, sex, CSA dose, CD34 and CD3 cell dose
n incidence of cGVHD. Multivariate analysis
howed LC30 450/L (RR 0.55, 95% CI 0.34-0.87;
 .01) was independently associated with an in-
reased incidence of cGVHD.
RM
Thirty-one of 157 (21%) patients died from non-
elapse causes, with a cumulative incidence of NRM
f 22%  4 % (Figure 4A). Causes of death were:
acterial/fungal infection (3); viral infection (8);
VHD-related (8); acute respiratory distress syn-
rome/idiopathic pneumonitis (8); late graft failure
1); transfusion reaction (1); intracranial bleeding (1);
otor vehicle accident (1). Factors associated with a
igniﬁcantly decreased risk of NRM were LC30
450/L (P  .0001) (Figure 4A); CD34 cell dose
reater than or equal to median (10% versus 30% for
igure 1. A, LC30 distribution in AML, ALL, and CML; B, comp
ounts posttransplantation between group with LC30 450/L anFigure 2. Time to A, neutrophil, and B, platelet engraftmenD34 cell dose less than median; P  .002), and
bsence of grade II-IV aGVHD (13% versus 27%,
 .02). In multivariate analysis, aGVHD (RR 2.3;
5% CI 1.1-4.9; P  .024), and LC30 450/L (RR
.6; 95% CI 1.2-10.6; P  .022) were independently
ssociated with an increased risk of NRM (Figure 4B).
elapse
Forty-three patients relapsed with a cumulative
ncidence of 36%  5% (Figure 5A). Median time to
elapse was 3.6 months (range: 1-37). On univariate
nalysis, increased risk of relapse was associated with
BSCT (majority CML patients) compared to BMT
31% versus 8%; P  .009), patients with ALL (52%
ersus 40% for AML and 11% for CML; P  .0001),
R disease (49% versus 5% for SR disease; P 
0001); absence of cGVHD (44% versus 17% for
atients with cGVHD; P .001) and LC30450/L
P  .009) (Figure 5A). There was no effect of age,
ex, CSA dose, or CD34 and CD3 cell dose on
ncidence of relapse. Multivariate analysis showed HR
isease (RR 15.6; 95% CI 5.4-45.1; P  .001), LC30
450/L (RR 3.0; 95% CI 1.5-6.0; P  .002), and
bsence of cGVHD (RR 0.32; 95% CI 0.16-0.65; P 
001) to be independently associated with an increased
isk of relapse. Cumulative incidence of relapse in
elation to disease risk status and LC30 is shown in
igure 5B. Patients with SR disease who achieved an
C30 of450/L had no relapse. In contrast patients
ith HR disease who failed to achieve LC30 of 450/
L, experienced a relapse rate of 77%  9%. Inter-
LC30, day 60 lymphocyte (LC60), and day 90 lymphocyte (LC90)
/L.arisont in patients with LC30 450/L versus 450/L.
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B. N. Savani et al.1220stingly, the impact of LC30 was only found in AML/
DS and CML, but not in ALL (whether analyzed
ither by cohort median or the disease speciﬁc median
alue of LC30; Figure 5C).
igure 3. Cumulative incidence of A, aGVHD, and B, cGVHD and
ncidence in patients with LC30 above and below 450/L.
igure 4. A, Cumulative incidence of nonrelapse mortality;
d, LC30, disease risk (HR, high risk; SR, standard risk), and NRM.urvival
Currently, 87 of 157 patients are alive and 83 are
isease free (actuarial OS is shown in Figure 6A). In
nivariate analysis, factors associated with improved
urvival were SR risk disease (81% versus 31% for HR
isease; P  .001), higher LC30 450/L (P  .001)
Figure 1A), CD34 cell dose above median of 5.0 
06/kg (67% versus 44%; P  .002), absence of
GVHD (grade II-IV) (P  .03), and development of
GVHD (79% versus 48%; P  .0001). There was no
mpact of type of SCT, age, sex, CD3 cell, and CSA
ose on survival.
Multivariate Cox regression analysis showed SR
isease (RR 7.1, 95% CI 3.2-15.5; P  .0001), LC30
450/L (RR 2.7, 95% CI 1.03-5.1; P  .047), and
igure 5. A, Cumulative incidence of relapse; B, LC30, disease risk
HR, high risk; SR, standard risk), and relapse; C, LC30 and relapse
n acute lymphoblastic leukemia (ALL).evelopment of cGVHD (RR 0.44, 95% CI 0.23-0.83;
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Transplant Outcome after Allogeneic Stem Cell Transplantation 1221 .01) were independently associated with improved
urvival.
Interestingly, patients with HR disease and those
atients who failed to achieve an LC30 of at least
50/L had very poor outcomes, with an actuarial
urvival of only 15%  6%. However, the patients
ith SR disease and LC30 of 450/L had an actu-
rial survival of 95%  3.5% (Figure 6B). In disease-
peciﬁc analysis, there was no impact of LC30 on
urvival in ALL compared to AML and CML (ana-
yzed with both cohort median and disease speciﬁc
edian value of LC30; Figure 6C).
ISCUSSION
Our results highlight a powerful predictive effect
igure 6. A, Overall survival; B, LC30, disease risk (HR, high risk;
R, standard risk), and survival; C, LC30 and survival in acute
ymphoblastic leukemia (ALL).f the day 30 posttransplant lymphocyte count (LC30) rn transplant outcome. When treated as a dichoto-
ous variable (absolute lymphocyte count above or
elow the median of 448/L), the LC30 emerged as a
nique, and powerful factor for predicting survival,
RM, aGVHD, and relapse. The only other factor
igniﬁcantly affecting outcomes in multivariate analy-
is were the well-established variables known to affect
ransplant outcome (disease status, and development
f aGVHD or cGVHD). The differences in actuarial
utcome were not only signiﬁcant between high and
ow LC30 sets but also associated with, notably, an RR
f 3.0 for lower relapse with higher LC30. Beneﬁcial
ffects of LC30 were not seen in ALL despite higher
C30 numbers in our study. These results should be
nterpreted with caution because of the small sample
ize of the ALL group (n  29) with a preponderance
f HR disease (n  26).
These data conﬁrm other observations indicating
he importance of lymphocyte recovery as a prognos-
ic factor for outcome after allogeneic SCT [1-4,12].
he measurement of lymphocyte count has practical
igniﬁcance because it identiﬁes a group of patients
notably HR patients with poor lymphocyte recovery)
ho might be suitable candidates for early interven-
ions or aggressive approaches to improve transplant
utcome. Other studies also show early lymphocyte
ecovey to be correlated with better outcome in
on-T cell-depleted transplants [1,3,12], particularly
n myelogenous leukemias. Early lymphocyte recovery
as also been shown to identify a patient subgroup at
isk for increased NRM (from infections and
GVHD), and graft failure [4,6,7].
In this analysis we sought to validate the widely used
hoice of days 21-30 for measuring lymphocyte count
or predictive purposes posttransplant. We showed that
C30 as a dichotomous value above or below the
edian reliably identiﬁed patient groups with either a
elatively high or a relatively low lymphocyte count
etween day 14 to 90 posttransplant. Thus, the mea-
urement of LC30 reliably characterized lymphocyte
ecovery over the entire ﬁrst 3 months posttransplant.
urthermore, we found that patients with higher than
edian LC30 were those who had a more rapid plate-
et and neutrophil recovery, suggesting that LC30
easurement is a surrogate for speed of donor en-
raftment (Figure 2).
Lymphocytes recovering in the ﬁrst month post-
ransplant consist of 2 major populations: NK cells
nd CD3 T cells. NK cells recover early after allo-
eneic SCT, generally about 3-4 days earlier than
ranulocyte and monocytes [8,13-15] but early recov-
ry of NK cell function does not occur in patients
ecovering from chemotherapy without stem cell sup-
ort [16]. Our earlier analyses in a small CML patient
ohort from this dataset indicated that NK cell and
otal lymphocyte count on day 30 were strongly cor-
elated [17]. Our data point to the transplanted CD34
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B. N. Savani et al.1222ell as the origin of recovering NK cells, because all
ransplants were selected for CD34 cells and depleted
f lymphocytes using a cocktail of anti-CD2, CD6,
nd CD7 antibodies. This cocktail would largely elim-
nate mature CD2 NK cells from the graft. Further-
ore, we found that the CD34 dose and LC30 was
ositively correlated. There is some data relating NK
ell recovery to transplant outcome: Scholl et al. [18]
howed that patients with better NK cell recovery had
ess severe aGVHD. In our previous report patients
ith CML had better leukemia control early post-
ransplant if they achieved higher than median NK
ell counts [7].
A role for donor CD3 T cells in early lympho-
yte recovery and subsequent clinical outcome ap-
eared to be a less likely explanation for our ﬁndings,
ecause donor T cell percentage varied between 0%
nd 100% on day 14 or day 30, and chimerism did not
orrelate with high or low LC30. In these T cell-
epleted SCT, T cell engraftment is characteristically
low and variable. Interestingly, in an earlier analysis
e did not ﬁnd any beneﬁt on outcome for early
omplete donor lymphoid chimerism in a subset of
32 patients in this series [11].
The observation that a GVL effect of LC30 was
ot found in ALL patients and the ﬁnding that better
K recovery on D30 was predictive for less aGVHD
ears a striking resemblance to the ﬁndings of the
erugia transplant group in haploidentical T cell-
epleted transplants who related NK KIR incompat-
bility (as a surrogate for donor-versus-recipient NK
lloreactivity) with a survival beneﬁt, less aGVHD,
nd a beneﬁcial effect on relapse in myeloid but not
ymphoid malignancies [19]. The relationship be-
ween NK alloreactivity and NK recovery posttrans-
lant is unclear, but the similarity of the relationship
etween NK characteristics and outcome in the Pe-
ugia series and our own HLA identical T cell-de-
leted transplants suggest that KIR expression might
n some way affect the pace of NK recovery.
In conclusion, LC30 appears to be a surrogate for
obust engraftment of all hematopoietic lineages, in-
luding NK cells. Because the lymphocyte count is
eliably and widely measured in most transplant
enters, and can be retrieved from retrospective
ransplant data, analyses of large patient groups
ransplanted with different regimens to determine
he general predictive value of LC30 measurement
hould be possible. Such studies might deﬁne the
ypes of diseases and transplant approaches that
ave the most impact from the pattern of lympho-
yte recovery and lead to development of patient-
peciﬁc strategies to improve outcome in those who
ail to achieve satisfactory lymphocyte counts in the
rst month posttransplant.CKNOWLEDGMENTS
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